The key near-term catalyst is the CUV105 vitiligo topline data in December 2026, which will determine the future of the vitiligo program and growth strategy. The proposed corporate restructuring to a Nasdaq-listed holding company adds a layer of strategic uncertainty. Monitor for any updates on the transaction timeline and regulatory feedback on CUV105.
Price Chart
Executive Summary
Clinuvel Pharmaceuticals filed its annual report on Form 20-F for fiscal year ended June 30, 2026, reporting revenue of $64.3 million (up from $61.1 million in FY2025), net income of $23.2 million (flat vs $23.1 million), and cash and short-term investments of $174 million. The filing details the ongoing CUV105 Phase III vitiligo trial with topline results expected in December 2026, the proposed corporate restructuring to redomicile to a new holding company and list on Nasdaq, and the recent Health Canada approval of SCENESSE for EPP. Revenue growth was modest at 5.2% YoY, operating income improved slightly, but the company faces binary risk from the upcoming CUV105 readout and execution risk on the proposed transaction.
Key Facts
- Revenue for FY2026 was $64,315,354, up from $61,120,888 in FY2025 and $57,911,843 in FY2024.
- Net income for FY2026 was $23,177,834, essentially flat compared to $23,122,864 in FY2025 and $23,346,174 in FY2024.
- Cash and cash equivalents plus short-term investments totaled $174,011,268 as of June 30, 2026.
- SCENESSE remains the sole revenue source, accounting for 100% of total revenue.
- Two customers accounted for 26% of FY2026 revenue.
- Topline results from the CUV105 Phase III vitiligo trial are expected in December 2026.
- On August 27, 2026, the Board announced it is considering a transaction to create a new foreign holding company, list on Nasdaq, and delist from the ASX.
- Health Canada approved SCENESSE for EPP in July 2026.
- Orphan drug exclusivity for SCENESSE expired in the U.S. in October 2026.
- The company's market cap is $254M with a normal daily move of 4.1%.
Financial Impact
Revenue grew 5.2% YoY to $64.3M; net income flat at $23.2M; cash and investments $174M; no debt.
Risk Factors
- CUV105 vitiligo trial topline results may be negative or inconclusive, potentially ending the vitiligo program.
- Proposed corporate restructuring may not be completed on the proposed terms or at all, incurring costs and management distraction.
- Expiration of U.S. orphan drug exclusivity in October 2026 could invite generic competition.
- Revenue concentration in two customers (26%) and sole-source API manufacturer in China create supply chain and geopolitical risk.
- Key patents for afamelanotide treatment of photodermatoses expire in 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001493152-26-049364 |
| Exhibit: ex97-1.htm | 0001493152-26-049364 |
| Exhibit: ex12-2.htm | 0001493152-26-049364 |
| Exhibit: ex12-1.htm | 0001493152-26-049364 |
| Exhibit: ex13-2.htm | 0001493152-26-049364 |
| Exhibit: ex13-1.htm | 0001493152-26-049364 |
| Document: 0001493152-26-049364-index-headers.html | 0001493152-26-049364 |
| Document: 0001493152-26-049364-index.html | 0001493152-26-049364 |
| Document: 0001493152-26-049364.txt | 0001493152-26-049364 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | 20-F | $4.94 | awaiting T+20 | awaiting T+20 | $5.07 (+2.63%) |
Oct 30, 2026 2d ago | 6-K | $4.94 | awaiting T+20 | awaiting T+20 | $5.07 (+2.63%) |
Oct 15, 2026 17d ago | 6-K | $5.06 | awaiting T+20 | awaiting T+20 | $5.07 (+0.20%) |
Oct 7, 2026 25d ago | 6-K | $5.80 | awaiting T+20 | awaiting T+20 | $5.07 (−12.59%) |
Oct 2, 2026 4w ago | 6-K | $6.03 $5.07 | ▼ −15.92% | ▼ −14.11% | $5.07 (−15.92%) |
Oct 1, 2026 4w ago | 6-K | $5.66 $5.15 | ▼ −9.01% | ▼ −9.71% | $5.07 (−10.42%) |
Aug 27, 2026 9w ago | 6-K | $6.77 $5.78 | ▼ −14.62% | ▼ −14.12% | $5.07 (−25.11%) |
Aug 27, 2026 9w ago | Press Release | $6.77 $5.78 | ▼ −14.62% | ▼ −14.12% | $5.07 (−25.11%) |
Aug 20, 2026 10w ago | 6-K | $7.80 $5.90 | ▼ −24.36% | ▼ −24.36% | $5.07 (−35.00%) |
Jul 23, 2026 14w ago | 6-K | $6.95 $7.80 | ▲ +12.23% | ▲ +8.92% | $5.07 (−27.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers